191 related articles for article (PubMed ID: 34564032)
41. Anticancer effect evaluation of iridium(III) complexes targeting mitochondria and endoplasmic reticulum.
Wang Y; Li Y; Chen J; Liu H; Zhou Y; Huang C; Liang L; Liu Y; Wang X
J Inorg Biochem; 2023 Jan; 238():112054. PubMed ID: 36335745
[TBL] [Abstract][Full Text] [Related]
42. Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes.
Jiang GB; Zhang WY; He M; Gu YY; Bai L; Wang YJ; Yi QY; Du F
J Inorg Biochem; 2021 Dec; 225():111616. PubMed ID: 34555601
[TBL] [Abstract][Full Text] [Related]
43. Lysosome-targeted ruthenium(II) complexes induce both apoptosis and autophagy in HeLa cells.
Pan NL; Liao JX; Huang MY; Zhang YQ; Chen JX; Zhang ZW; Yang ZX; Long XE; Wu XT; Sun J
J Inorg Biochem; 2022 Apr; 229():111729. PubMed ID: 35066350
[TBL] [Abstract][Full Text] [Related]
44. Iridium(III) complex induces apoptosis in HeLa cells by regulating mitochondrial and PI3K/AKT signaling pathways: In vitro and in vivo experiments.
He SF; Han WC; Shao YY; Zhang HB; Hong WX; Yang QH; Zhang YQ; He RR; Sun J
Bioorg Chem; 2023 Dec; 141():106867. PubMed ID: 37734195
[TBL] [Abstract][Full Text] [Related]
45. Iridium(III) complexes conjugated with naproxen exhibit potent anti-tumor activities by inducing mitochondrial damage, modulating inflammation, and enhancing immunity.
Xie K; Lu XY; Zhu H; Zhu LY; Li RT; Ye RR
Dalton Trans; 2024 May; 53(20):8772-8780. PubMed ID: 38712840
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis, and antitumor mechanism investigation of iridium(III) complexes conjugated with ibuprofen.
Chen SQ; Lu XY; Zhu LY; Zhu H; Li RT; Ye RR
J Inorg Biochem; 2024 Aug; 257():112596. PubMed ID: 38759264
[TBL] [Abstract][Full Text] [Related]
47. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
48. Mitochondria-targeted phosphorescent cyclometalated iridium(III) complexes: synthesis, characterization, and anticancer properties.
Li Y; Liu B; Xu CX; He L; Wan YC; Ji LN; Mao ZW
J Biol Inorg Chem; 2020 Jun; 25(4):597-607. PubMed ID: 32232583
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and anticancer activity in vitro and in vivo evaluation of iridium(III) complexes on mouse melanoma B16 cells.
Yuan Y; Shi C; Wu X; Li W; Huang C; Liang L; Chen J; Wang Y; Liu Y
J Inorg Biochem; 2022 Jul; 232():111820. PubMed ID: 35421766
[TBL] [Abstract][Full Text] [Related]
50. Mixed-ligand iridium(iii) complexes as photodynamic anticancer agents.
Zheng Y; He L; Zhang DY; Tan CP; Ji LN; Mao ZW
Dalton Trans; 2017 Aug; 46(34):11395-11407. PubMed ID: 28813052
[TBL] [Abstract][Full Text] [Related]
51. Lysosome-targeted cyclometalated iridium(III) complexes: JMJD inhibition, dual induction of apoptosis, and autophagy.
Lu JJ; Ma XR; Xie K; Chen MR; Huang B; Li RT; Ye RR
Metallomics; 2022 Sep; 14(9):. PubMed ID: 36073756
[TBL] [Abstract][Full Text] [Related]
52. Ruthenium(II) polypyridyl complexes induce BEL-7402 cell apoptosis by ROS-mediated mitochondrial pathway.
Jiang GB; Zheng X; Yao JH; Han BJ; Li W; Wang J; Huang HL; Liu YJ
J Inorg Biochem; 2014 Dec; 141():170-179. PubMed ID: 25268891
[TBL] [Abstract][Full Text] [Related]
53. Diorganotin (IV) complexes with 4-nitro-N-phthaloyl-glycine: Synthesis, characterization, antitumor activity and DNA-binding studies.
Yan C; Zhang J; Liang T; Li Q
Biomed Pharmacother; 2015 Apr; 71():119-27. PubMed ID: 25960226
[TBL] [Abstract][Full Text] [Related]
54. Cyclometalated iridium(iii) complexes induce mitochondria-derived paraptotic cell death and inhibit tumor growth in vivo.
He L; Wang KN; Zheng Y; Cao JJ; Zhang MF; Tan CP; Ji LN; Mao ZW
Dalton Trans; 2018 May; 47(20):6942-6953. PubMed ID: 29721561
[TBL] [Abstract][Full Text] [Related]
55. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
56. Mitochondria-targeted cyclometalated iridium-β-carboline complexes as potent non-small cell lung cancer therapeutic agents.
Chen J; Guo X; Li D; Tang H; Gao J; Yu W; Zhu X; Sun Z; Huang Z; Chen L
Metallomics; 2023 Jun; 15(6):. PubMed ID: 37204038
[TBL] [Abstract][Full Text] [Related]
57. Cyclometalated iridium(III)-guanidinium complexes as mitochondria-targeted anticancer agents.
Song XD; Kong X; He SF; Chen JX; Sun J; Chen BB; Zhao JW; Mao ZW
Eur J Med Chem; 2017 Sep; 138():246-254. PubMed ID: 28668477
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and anticancer properties of ruthenium (II) complexes as potent apoptosis inducers through mitochondrial disruption.
Wan D; Tang B; Wang YJ; Guo BH; Yin H; Yi QY; Liu YJ
Eur J Med Chem; 2017 Oct; 139():180-190. PubMed ID: 28800456
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and evaluation of anticancer activity of ruthenium (II) polypyridyl complexes.
Tang B; Wan D; Lai SH; Yang HH; Zhang C; Wang XZ; Zeng CC; Liu YJ
J Inorg Biochem; 2017 Aug; 173():93-104. PubMed ID: 28511064
[TBL] [Abstract][Full Text] [Related]
60. New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies.
Jiang GB; Zhang WY; He M; Gu YY; Bai L; Wang YJ; Yi QY; Du F
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Feb; 227():117534. PubMed ID: 31685424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
